Itraconazol Tolife (Itraconazole)

• Itraconazole is an azole antifungal used to treat infections caused by susceptible fungi.
• Dermatophytosis: Reduces fungal skin infection and promotes lesion clearance.
• Onychomycosis: Improves nail appearance by eradicating the infecting dermatophytes.
• Systemic candidiasis: Controls invasive Candida infections in immunocompromised patients.
• Aspergillosis: Treats invasive disease caused by Aspergillus species.
• Blastomycosis: Helps resolve infection by inhibiting growth of Blastomyces dermatitidis.

• Itraconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase, a key step in ergosterol biosynthesis. By blocking conversion of lanosterol to ergosterol, the drug disrupts fungal cell membrane integrity, leading to increased permeability and inhibition of growth. The inhibition is concentration‑dependent and results in fungistatic activity at lower concentrations and fungicidal effects at higher levels.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset or queasiness.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, usually self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of congestive heart failure, especially in patients with pre‑existing conditions.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: blurred vision or photopsia.

When prescribing itraconazole, clinicians should consider several precautionary measures to ensure patient safety.

• Liver function monitoring: assess baseline enzymes and repeat during therapy.
• Drug‑interaction review: avoid concomitant use with strong CYP3A4 inhibitors or inducers.
• Cardiac assessment: evaluate for history of heart failure before initiating treatment.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Itraconazole has a notable interaction profile due to its effect on cytochrome P450 enzymes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase itraconazole levels and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug concentrations.
• Certain statins (e.g., simvastatin, lovastatin): heightened risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely)

• Antacids or proton pump inhibitors: may decrease absorption, monitor therapeutic response.
• Warfarin: potential alteration of INR, require more frequent coagulation monitoring.
• HIV protease inhibitors: may increase itraconazole exposure, adjust dose as needed.